$4.8B Roche-Spark deal delayed, once again
May 14, 2019 at 09:50 AM EDT
Roche and Spark Therapeutics are delaying their $4.8 billion deal for a third time to again give federal regulators more time to review the proposed sale of the Philadelphia gene therapy company.